VBI Vaccines/VBIV

$0.59

3.84%
-
1D1W1MYTD1YMAX

About VBI Vaccines

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Ticker

VBIV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Baxter

Employees

190

Headquarters

Cambridge, United States

VBI Vaccines Metrics

BasicAdvanced
$13.5M
Market cap
-
P/E ratio
-$11.87
EPS
1.91
Beta
-
Dividend rate

What the Analysts think about VBI Vaccines

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 2 analysts.
577.97% upside
High $6.00
Low $2.00
$0.59
Current price
$4.00
Average price target

VBI Vaccines Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-309.09% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$6.6M
842.86%
Net income
$-20.4M
-54.26%
Profit margin
-309.09%
-95.15%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell VBI Vaccines stock

Buy or sell VBI Vaccines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing